Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 8, 2000, Pages 963-978

  Stedman, C A M ^a   Barclay, M L ^a,b  

^a Department of Gastroenterology ^*  (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DUODENUM ULCER; HELICOBACTER PYLORI; LIVER METABOLISM; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT;

DUODENAL ULCER; ENZYME INHIBITORS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HUMANS; PROTON PUMPS; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0033859564     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00788.x     Document Type: Review

References (113)

1. + ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
2. 2 Huber R, Kohl B, Sachs G, et al. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
3. 3 Sachs G, Shin JM, Besancon M, et al. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993; 7(Suppl. 1): 4-12.
4. 4 Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-7.
5. 5 Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial of the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
6. 6 Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996; 8(Suppl. 1): S15-20.
7. 7 Andersson T, Andren K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557-63.
8. 8 Delhotal-Landes B, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458-70.
9. 9 Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22 438-46.
10. 10 Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70.
11. 11 Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Therapeut 1996; 34: 185-94.
12. 12 Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30.
13. 13 Gerloff J, Mignot A, Barth H, et al. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996; 50: 293-7.
14. 14 Reill L, Erhardt F, Heinzerling H, et al. Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH, serum pantoprazole and serum gastrin in man. Gastroenterology 1994; 106(Suppl.): A165(Abstract).
15. 15 Benet LZ, Zech K. Pharmacokinetics - a relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994; 8(Suppl. 1): 25-32.
16. 16 Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health-Syst Pharm 1996; 53: 1401-15.
17. 17 Brummer R-JM, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997; 42: 2132-7.
18. 18 Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
19. 19 Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Therapeut 1996; 34(Suppl. 1): S31-50.
20. 20 Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993; 45:367-71.
21. 14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40: 344-51.
22. 22 Lins RL, De Clercq I, Hartmann M, et al. Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment. Gastroenterology 1994; 106: A126(Abstract).
23. 23 Danz-Neeff H, Brunner G. Comparative kinetic studies with the three proton pump inhibitors omeprazole, lansoprazole and pantoprazole in patients with complete liver cirrhosis. Gastroenterology 1996; 110: A90(Abstract).
24. 24 Hoyumpa AM, Trevino-Alanis H, Grimes I, et al. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 1999; 21: 691-701.
25. 25 Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467-9.
26. 26 Breuel HP, Hartmann M, Bondy S, et al. Pantoprazole in the elderly: no dose-adjustment. Gut 1994; 35(Suppl. 4): A 77( Abstract).
27. 27 Andersson T, Regardh C-G, Dahl-Puustinen ML. Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415-6.
28. 28 Sohn MD, Kwon J-T, Kim H-K. Infuence of S-mephenytoin phenotype on the lansoprazole metabolism. Clin Pharmacol Ther 1996; 59: 137(Abstract).
29. 29 Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8(Suppl. 1): 33-8.
30. 30 Unge P, Andersson T. Drug interactions with proton pump inhibitors. Drug Safety 1997; 16: 171-9.
31. 31 Meyer UA. Interaction of proton pump inhibitors with cytochrome P450: consequences for drug interactions. Yale J Biol Med 1996; 69: 203-9.
32. 32 Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-30.
33. 33 Curi-Pedrosa R, Pichard L, Bonfils C, et al. Major implication of cytochrome P4503A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol 1993; 36: 156P.
34. 34 Kromer S, Postius R, Riedal WA, et al. BY 1023/SK & F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 1990; 254: 129-35.
35. +-ATPase inhibitor pantoprazole (BY1023/SK & F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991; 42: 347-55.
36. 36 Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl. 1): S21-5.
37. 37 Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48: 391-5.
38. 38 Granneman G, Winters EP, Locke CS, et al. Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics. Gastroenterology 1991; 100: A75(Abstract).
39. 39 Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-11.
40. 40 Rizzo N, Padoin C, Palombo S, et al. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 1996; 49: 491-5.
41. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170-80.
42. 42 Andersson T, Bergstrand R, Cederberg C, et al. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991; 101: 943-7.
43. 43 Humphries TJ, Nardi RV, Spera AC, et al. Coadministration of rabeprazole sodium (E3810) does not effect the pharmacokinetics of anhydrous theophylline or warfarin. Gastroenterology 1996; 110: A138(Abstract).
44. 44 Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235-41.
45. 45 Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543-5.
46. 46 Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458-63.
47. 47 Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 1994; 32: 385-99.
48. 48 Gugler R, Hartmann M, Rudi J, et al. Lack of interaction of pantoprazole and diazepam in man. Gastroenterology 1992; 102: A77(Abstract).
49. 49 Humphries TJ, Spera AC, Laurent AL, et al. Rabeprazole sodium (E3810), 20 mg daily does not affect the pharmacokinetics of phenytoin sodium in normal volunteers. Am J Gastroenterol 1996; 91: 1914(Abstract).
50. 50 Oosterhuis B, Jonkman JHG, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569-72.
51. 51 Humphries TJ, Spera AC, Laurent AL, et al. Coadministration of rabeprazole sodium (E3810) and digoxin results in a predictable interaction. Am J Gastroenterol 1996; 91: 1914(Abstract).
52. 52 Humphries TJ, Nardi RV, Spera AC, et al. Coadministration of rabeprazole sodium (E3810) and ketoconazole results in a predictable interaction with ketoconazole. Gastroenterology 1996; 110: A138(Abstract).
53. 53 Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
54. 54 Bruley Des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
55. 55 Blum RA, Shi H, Karol MD, et al. The comparative effects of lansoprazole, omeprazole and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013-23.
56. 56 Verdu EF, Fraser R, Armstrong D, et al. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994; 29: 1065-9.
57. 57 Geus WP, Mulder PG, Nicolai JJ, et al. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998; 12: 329-35.
58. 58 Seennsalu R, Iwarzon M, Janczewska I, et al. Dose-response comparison of lansoprazole and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers. Gastroenterology 1995; 108: A215(Abstract).
59. 59 Timmer W, Ripke H, Kleist P, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Meth Find Exp Clin Pharmacol 1995; 17: 489-95.
60. 60 Brunner G, Danz-Neeff H, Athmann N, et al. Comparison of pantoprazole (40 mg SID) versus omeprazole (40 mg SID) on intragastric pH and serum gastrin in healthy volunteers. Can J Gastroenterol 1997; 11(Suppl. A): S2.
61. 61 Koop H, Kuly S, Flug M, et al. Comparison of 24-h intragastric pH and 24-h gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole. Gut 1994; 35(Suppl. 4): A79(Abstract).
62. 62 Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 359-66.
63. 63 Florent C, Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur J Gastroenterol Hepatol 1997; 9: 195-200.
64. 64 Scholtz HE, Meyer BH, Luus HG. Comparison of the effects of lansoprazole, omeprazole and pantoprazole on 24-hour gastric pH in healthy males. SA Med J 1995; 85: 915(Abstract).
65. 65 Vcev A, Stimac D, Vceva A, et al. Lansoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croatica 1997; 51: 171-4.
66. 66 Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57.
67. 67 Corallo J, Vicari F, Forestier S, et al. Lansoprazole in acute treatment of reflux esophagitis. Gastroenterology 1993; 104: A58(Abstract).
68. 68 Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 224-8.
69. 69 Mee AS, Rowley JL, the Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757-63.
70. 70 Cordova-Villabos JA, Ramirez-Barba EJ, Ramirez-Covarrubias JC. Reflux esophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Preliminary report. Revista Gastroenterol Mexico 1996; 61: 306-9.
71. 71 Sekiguchi T, Horikoshi T, Nishioka T, et al. Clinical effect of proton pump inhibitors on oesophagitis [in Japanese]. Nipp Rinsho 1992; 50: 131-7.
72. 72 Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicenter trial). Eur J Gastroenterol Hepatol 1996; 8: 1101-6.
73. 73 Corinaldesi R, Valentini M, Belaiche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicenter study. Aliment Pharmacol Ther 1995; 9: 667-71.
74. 74 Hotz J, Gangl A, Heinzerling H. Pantoprazole vs omeprazole in acute reflux esophagitis. Gastroenterology 1996; 110: A136(Abstract).
75. 75 Mossner J, Holscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
76. 76 Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
77. 77 Carling L, Axelsson CK, Forssell H, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther 1998; 12: 985-90.
78. 78 Jaspersen D, Diehl KL, Schoeppner H, et al. A comparison of omeprazole, lansoprazole and pantoprazole in maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998; 12: 49-52.
79. 79 Florent C, Audigier JC, Boyer J, et al. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: a multicentre study. Eur J Gastroenterol Hepatol 1994; 6: 1135-9.
80. 80 Witzel L, Gutz H, Huttemann W, et al. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995; 9: 19-24.
81. 81 Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of gastric ulcer-a European multicentre study. Aliment Pharmacol Ther 1998; 12: 789-95.
82. 82 Chang F-Y, Chiang C-Y, Tam T-N, et al. Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. J Gastroenterol Hepatol 1995; 10: 595-601.
83. 83 Dobrilla G, Piazzi L, Fiocca R. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. Clin Ther 1999; 21: 1321-32.
84. 84 Ekstrom P, Carling L, Unge P, et al. Lansoprazole versus omeprazole in active duodenal ulcer. Scand J Gastroenterol 1995; 30: 210-5.
85. 85 Petite J-P, Slama J-L, Licht H, et al. Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. Gastroenterol Clin Biol 1993; 17: 334-40.
86. 86 Louw JA, van Rensburg C, Simjee AE, et al. Lansoprazole versus omeprazole in duodenal ulcer healing. Safr Med J 1993; 83: 777.
87. 87 Beker JA, Porro GB, Bigard M-A, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 407-10.
88. 88 Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration-a multicentre study. Aliment Pharmacol Ther 1995; 9: 411-6.
89. 89 Italian Group for the Study of Pantoprazole. Efficacy and tolerability of pantoprazole vs omeprazole in the treatment of duodenal ulcer. Argoment Gastroenterol Clin 1994; 7: 271-5.
90. 90 Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179-86.
91. 91 Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol 1998; 27(Suppl. 1): S163-9.
92. 92 Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500.
93. 93 Pipkin GA, Williamson R, Wood JR. One-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-37.
94. 94 Mullhaupt B, Fluckiger T, Frohli P, et al. One week low dose triple therapies with lansoprazole or omeprazole are equally effective for H pylori eradication and ulcer healing. Gastroenterology 1996; 110: A202(Abstract).
95. 95 Spinzi GC, Bierti L, Bortoli A, et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 433-8.
96. 96 Catalano F, Privitera U, Branciforte G, et al. Omeprazole vs. two different doses of lansoprazole in triple therapy on H. pylori positive duodenal ulcer. Gut 1996; 39(Suppl. 2): A32(Abstract).
97. 97 Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 163-8.
98. 98 Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
99. 99 Jones R, Crouch SL. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 1999; 13: 413-9.
100. 100 Wilde MI, McTavish D. Omeprazole. An update on its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
101. 101 Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82.
102. 102 Koury SI, Stone CK, La Charite DD. Omeprazole and the development of acute hepatitis. Eur J Emerg Med 1998; 5: 467-9.
103. 103 Viana de Miguel C, Alvarez Garcia M, Sanchez Sanchez A, et al. Lansoprazole-induced hepatitis [in Spanish]. Med Clin (Barc) 1997; 108: 599.
104. 104 Yip D, Kovac S, Jardine M, et al. Omeprazole-induced interstitial nephritis. J Clin Gastroenterol 1997; 25: 450-2.
105. 105 Schonhofer PS, Werner B. Ocular damage associated with proton pump inhibitors. Br Med J 1997; 314: 1805.
106. 106 Lessell S. Omepraxole and ocular damage. Concerns on safety of drug are unwarranted. Br Med J 1998; 316: 67.
107. 107 Garcia Rodriguez LA, Mannino S, Wallander MA, et al. A cohort study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol 1996; 42: 213-6.
108. 108 Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994; 8(Suppl. 1): 39-46.
109. 109 Yeomans ND, Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 2000; 14: 267-271.
110. 10 Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000; 14: 15-22.
111. 11 Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994; 32: 466-73.
112. 112 Zomorodi K, Houston JB. Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol 1996; 42: 157-62.
113. 113 Dammann HG, Fuchs W, Richter G, et al. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 359-64.